New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
05:34 EDTABBVAbbVie submits MAAs to EMA for investigational HCV therapy
AbbVie submitted marketing authorization applications, or MAAs, to the European Medicines Agency, or EMA, seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1, or GT1, hepatitis C virus, or HCV, infection. The MAAs are supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date, which consists of six Phase III studies that include more than 2,300 patients in over 25 countries.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
18:03 EDTABBVAbbVie says endpoint achieved in Phase 3 study of all-oral treatment for Hep C
AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir in patients with genotype 1b chronic hepatitis C virus infection in Japan. The primary endpoint of the GIFT-I study was achieved, demonstrating a 95% sustained virologic response rate at 12 weeks post treatment in the sub-group of previously untreated, non-cirrhotic adult GT1b Japanese patients who were eligible for therapy with interferon (IFN) and had a high viral load.
14:33 EDTABBVAbbVie comments affirm 25/75 HCV market split with Gilead, says Wells Fargo
Subscribe for More Information
14:27 EDTABBVAbbVie added to short-term buy list at Deutsche Bank
09:48 EDTABBVAbbVie sees 100bps of gross margin improvement if FX rates are stable
09:35 EDTABBVAbbVie sees high teens revenue growth on an operational basis in FY15
Subscribe for More Information
09:34 EDTABBVAbbVie sees high teens revenue growth on an operational basis in FY15
Subscribe for More Information
09:33 EDTABBVAbbVie sees Q1 adjusted EPS 82c-84c, consensus 85c
09:30 EDTABBVAbbVie confirms FY15 guidance issued earlier this month
Subscribe for More Information
07:50 EDTABBVAbbVie reports Q4 Humira sales up 10.6% to $3.36B
Subscribe for More Information
07:49 EDTABBVAbbVie sees FY15 adjusted EPS $4.25-$4.45, consensus $4.37
Subscribe for More Information
07:48 EDTABBVAbbVie reports Q4 GAAP revenue $5.45B, consensus $5.36B
Subscribe for More Information
07:48 EDTABBVAbbVie reports Q4 adjusted EPS 89c, consensus 86c
Subscribe for More Information
January 29, 2015
15:37 EDTABBVNotable companies reporting before tomorrow's open
Subscribe for More Information
14:46 EDTABBVAbbVie technical comments ahead of earnings, levels to watch
The shares have been trending down since hitting the 52-week high of $70.76 back in early December of last year. At the current price of $63.01, the first important support level to watch on negative news or outlook would be at the 200-day moving average, last at $58.04. A test and a bounce there would be bullish, while a breakdown would be bearish for the longer-term uptrend. Levels to watch below the 200-day are at $56.51, and then at $55.80. If the news is a positive surprise, the first resistance level of note as a potential upside objective is at the $65 area. A breakout above $65 would turn the trend to bullish, with next resistance levels at $67.16, $68.29, and the 52-week high at $70.76.
13:38 EDTABBVEarnings Preview: AbbVie reports Q4 results after FDA Viekira Pak approved
AbbVie (ABBV) is scheduled to report fourth quarter earnings before the market open on Friday, January 30 with a conference call scheduled for 9:00 am ET. EXPECTATIONS: Analysts are looking for earnings per share of 86c on revenue of $5.36B, according to First Call. The consensus range for EPS is 82c-90c on revenue of $5.17B-$5.59B. LAST QUARTER: AbbVie reported third quarter EPS of 89c, considerably higher than consensus estimates of 77c, on revenue of $5.02B against estimates of $4.82B. The company raised its fiscal year 2014 EPS view to $3.25-$3.27 from $3.06-$3.16 against consensus estimates of $3.16. On its Q3 earnings conference call the company said it is "well on track" to exceed original Humira sales forecast for FY14. CEO Richard Gonzalez commented on the quarter, "Our Q3 results reflect the strong performance of our business with double-digit growth from Humira and several other key brands. Our underlying business grew nearly 14% in the quarter excluding lipids, We exceeded our outlook for the quarter and have significantly raised our original 2014 guidance. In Q4, we look forward to the U.S. approval of our interferon-free HCV combination, which will further accelerate sales and earnings growth in 2015 and beyond." STREET RESEARCH: On January 9, BofA/Merrill downgraded AbbVie to Neutral based on valuation with a price target of $70. On January 6, UBS raised its price target on AbbVie shares to $76 from $72, citing increased market share assumptions for the company's Viekira Pak Hep C regimen and a more favorable view of the regimen's approval chances in the EU. The firm maintained its Buy rating on the stock. PRICE ACTION: AbbVie shares are up around 3% since the company's last earnings report on October 31 and are up around 1.5% to $62.83 in midday trading ahead of Friday's earnings release.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use